Annual Congress: Hematologic Malignancies

2020-hem-web-header

Register now for the NCCN 2022 Annual Congress: Hematologic Malignancies™ to access high-quality educational content, networking opportunities, and more!

Dates: Friday, October 14, 2022 – Saturday, October 15, 2022

Location: New York Marriott Marquis | New York, New York

Attendance options: Attend either in-person in New York or remotely through a virtual event platform. All attendees will have full access to:

  • All live and on-demand sessions
  • An opportunity to engage in interactive Q&A sessions with speakers
  • The NCCN Exhibition Hall
Visit the Congress Summary page to learn more and register!
See session topics, learning objectives, speakers, and more!
Enjoy the same low fee for in-person or virtual registration and view discounts!

 

 

Join us in New York!

Those attending in-person will have additional networking opportunities, including a Welcome Reception on Friday evening. Those attending onsite will also receive complimentary breakfast, lunch, and refreshments during breaks.

Attention In-Person Attendees! Proof of COVID-19 vaccination will be required for on-site attendance. Please click here for additional details. Instructions on how to submit proof of vaccination will be sent to all in-person registrants closer to the date of the meeting.

Continuing Education

This 1.5-day, CE-certified event will focus on the latest advances in hematologic malignancies. Chaired by Andrew D. Zelenetz, MD, PhD, from Memorial Sloan Kettering Cancer Center, the program will feature panel discussions with world-renowned experts, interactive presentations, and challenging patient cases that highlight recent updates to the NCCN Guidelines®, new and emerging therapeutic agents, and practical management strategies for patients with hematologic malignancies.

This year’s agenda includes 18 on-demand and live educational sessions designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies. This program is approved for AMA PRA Category 1 Credit and ABIM, ABPath, and ABMS MOC for physicians and is also certified for credit for nurses, pharmacists, and other oncology professionals.

Agenda topics include: 

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • CLL/SLL
  • Chronic Myeloid Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Hematopoietic Growth Factors
  • Hodgkin Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Neoplasms
  • Systemic Amyloidosis
  • Systemic Mastocytosis
  • Vaccines

For CE program supporter opportunities, contact Lisa Perfidio, Senior Manager, CE Supporter Outreach.

This activity is supported by educational grants from:

  • AstraZeneca
  • GlaxoSmithKline
  • Lilly
  • Novartis
  • Seagen
This activity is supported by independent educational grants from:

  • Incyte
  • Merck  & Co., Inc.

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

This activity is supported by educational funding provided by Amgen.

This activity is supported by a medical education grant from Karyopharm Therapeutics.

 

 

Exhibition Hall

Visit the NCCN Exhibition Hall in-person and virtually for networking opportunities and to gather the latest information from industry-sponsored exhibits, the Patient Advocacy Pavilion, and more. 

View Exhibitor Prospectus

 

For exhibitor opportunities, contact Jennifer Tredwell, Vice President, Marketing and Communications

Related Program

2022-HEM-Nursing-728x90

NCCN 2022 Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™
Saturday, October 15, 2022
New York, New York
Registration is separate from the NCCN Hematologic Malignancies Congress. Virtual attendance option available.

Register Now  View Agenda

 

View Recorded Presentations

 

Topics Include:

  • Updates in the Management of Newly Diagnosed Acute Myeloid Leukemia
  • Debate – Response Milestones that Matter in Chronic Myeloid Leukemia: MMR vs. CCyR
  • Patient Case Studies and Panel Discussion: Leukemias
  • Mutational Landscape in Myeloproliferative Neoplasms: Implications on Prognosis and Clinical Management
  • Recommendations for Managing Adults with Histiocytic Neoplasms: New NCCN Guidelines
  • Newly Diagnosed Multiple Myeloma: How Many Drugs are Enough?
  • Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma
  • Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
  • Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Minimal Residual Disease Assessment in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Is it Ready for Routine Clinical Practice?
  • Updates in the Management of Early-Stage Diffuse Large B-Cell Lymphoma
  • Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease
  • Patient Case Studies and Panel Discussion: Lymphomas
  • Mantle Cell Lymphoma: Updates in the Management of Relapsed/Refractory Disease
  • Optimizing First-Line Therapy for Advanced Stage Classic Hodgkin Lymphoma

View Recorded Presentations


Accreditation

This program is approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals.


Supporters

This activity is supported by educational grants from: 

  • AstraZeneca
  • Daiichi Sankyo 
  • Gilead Sciences, Inc. and Kite, A Gilead Company
  • GlaxoSmithKline
  • Novartis
  • Pfizer Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Seagen Inc. (formerly Seattle Genetics, Inc.)
  • Takeda

This activity is supported by independent medical education grants from:

  • ADC Therapeutics
  • Bristol Myers Squibb
  • MorphoSys
  • Pharmacyclics LLC and Janssen and Jazz Pharmaceuticals

This educational activity is supported by a medical education grant from Karyopharm® Therapeutics.

This activity is supported by an independent educational grant from Merck & Co., Inc.

Related Programs

Recorded Presentations from the NCCN 2021 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™ are now available.

View Recorded Presentations

 

Save the dates!

NCCN 2023 Annual Congress: Hematologic Malignancies™
Hilton San Francisco Union Square • San Francisco, California
Friday, September 22, 2023 – Saturday, September 23, 2023